Your browser doesn't support javascript.
loading
An improved approach to generate IL-15+/+/TGFßR2-/- iPSC-derived natural killer cells using TALEN.
Chen, An-Ping; Gao, Peng; Lin, Liang; Ashok, Preeti; He, Hongzhi; Ma, Chao; Zou, David Li; Allain, Vincent; Boyne, Alex; Juillerat, Alexandre; Duchateau, Philippe; Rath, Armin; Teper, Daniel; Arulanandam, Antonio; Chang, Hao-Ming; Eyquem, Justin; Li, Wei.
Affiliation
  • Chen AP; Cytovia Therapeutics, Inc., Natick, MA, USA. Electronic address: anping.chen@cytoviatx.com.
  • Gao P; Cytovia Therapeutics, Inc., Natick, MA, USA.
  • Lin L; Cytovia Therapeutics, Inc., Natick, MA, USA.
  • Ashok P; Cytovia Therapeutics, Inc., Natick, MA, USA.
  • He H; Cytovia Therapeutics, Inc., Natick, MA, USA.
  • Ma C; Cytovia Therapeutics, Inc., Natick, MA, USA.
  • Zou DL; Cytovia Therapeutics, Inc., Natick, MA, USA.
  • Allain V; Gladstone-University of California, San Francisco Institute of Genomic Immunology, San Francisco, CA, USA; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA; Université Paris Cité, INSERM UMR976, Hôpital Saint-Louis, Paris, France.
  • Boyne A; Cellectis Inc, New York, NY, USA.
  • Juillerat A; Cellectis Inc, New York, NY, USA.
  • Duchateau P; Cellectis, Paris, France.
  • Rath A; Cytovia Therapeutics, Inc., Aventura, FL, USA.
  • Teper D; Cytovia Therapeutics, Inc., Aventura, FL, USA.
  • Arulanandam A; Cytovia Therapeutics, Inc., Natick, MA, USA.
  • Chang HM; Cytovia Therapeutics, Inc., Natick, MA, USA.
  • Eyquem J; Gladstone-University of California, San Francisco Institute of Genomic Immunology, San Francisco, CA, USA; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Li W; Cytovia Therapeutics, Inc., Natick, MA, USA. Electronic address: wei.li@cytoviatx.com.
Cell Rep Methods ; 4(9): 100857, 2024 Sep 16.
Article in En | MEDLINE | ID: mdl-39260365
ABSTRACT
We present a TALEN-based workflow to generate and maintain dual-edited (IL-15+/+/TGFßR2-/-) iPSCs that produce enhanced iPSC-derived natural killer (iNK) cells for cancer immunotherapy. It involves using a cell lineage promoter for knocking in (KI) gene(s) to minimize the potential effects of expression of any exogenous genes on iPSCs. As a proof-of-principle, we KI IL-15 under the endogenous B2M promoter and show that it results in high expression of the sIL-15 in iNK cells but minimal expression in iPSCs. Furthermore, given that it is known that knockout (KO) of TGFßR2 in immune cells can enhance resistance to the suppressive TGF-ß signaling in the tumor microenvironment, we develop a customized medium containing Nodal that can maintain the pluripotency of iPSCs with TGFßR2 KO, enabling banking of these iPSC clones. Ultimately, we show that the dual-edited IL-15+/+/TGFßR2-/- iPSCs can be efficiently differentiated into NK cells that show enhanced autonomous growth and are resistant to the suppressive TGF-ß signaling.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Killer Cells, Natural / Interleukin-15 / Induced Pluripotent Stem Cells / Receptor, Transforming Growth Factor-beta Type II Limits: Humans Language: En Journal: Cell Rep Methods Year: 2024 Document type: Article Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Killer Cells, Natural / Interleukin-15 / Induced Pluripotent Stem Cells / Receptor, Transforming Growth Factor-beta Type II Limits: Humans Language: En Journal: Cell Rep Methods Year: 2024 Document type: Article Country of publication: